![](https://tracker.live.rns-distribution.com/track.live-rns/5166074_75d1671758db0ed18eba2dbba83793b2.png)
Haleon plc announces changes to the Board
1 May 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that following Deirdre Mahlan's appointment as President, Chief Executive Officer and Chairperson of the Board of The Duckhorn Portfolio, Inc. (NYSE: NAPA), Deirdre will be stepping down from her role as Non-Executive Director and Chair of the Audit & Risk Committee of Haleon. Deirdre has agreed to continue as Non-Executive Director and Chair of the Audit & Risk Committee of Haleon until a successor has been identified.
Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would like to thank Deirdre for her considerable contributions to the Board and for chairing the Audit & Risk Committee. I wish her all the best for the future. A search for her successor is now underway."
Contacts
Zoë Bird +44 7736 746167
Sonya Ghobrial +44 7392 784784
Email: corporate.media@haleon.com
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.